Orexo strengthens its commercial knowhow and appoints Nikolaj Sørensen as Chief Commercial Officer

Orexo strengthens its commercial knowhow and appoints Nikolaj Sørensen
as Chief Commercial Officer

 

Uppsala, Sweden, September 16, 2011 - Orexo AB (STO: ORX) appoints
Nikolaj Sørensen as Chief Commercial Officer effective October 1, 2011.
Nikolaj has extensive experience of the pharmaceutical industry and will
be responsible for Orexo's commercial operations as well as development
of the company's commercial strategies. His international commercial
experience is a key asset in Orexo's goal to develop, market and sell
proprietary products. Nikolaj will be reporting to the CEO and will be
part of the company's executive management team.

Nikolaj Sørensen has a Master of Science in Business and Economics and
previously worked at Pfizer where he was i.a. Director and Brand Team
Leader for Pfizer's leading pain treatment product in Europe and Canada.
At Pfizer, Nikolaj also worked as Head of Business Development and
Director of Strategic Planning, acted as Business Area Director for
primary care products, and as Managing Director and Chairman of the
board for Pfizer AB. In addition, Nikolaj has been a member of the Board
of the Swedish Pharmaceutical Industry Association (LIF) for the past
few years.

Prior to working at Pfizer, Nikolaj was a consultant at Boston
Consulting Group (BCG), focusing on life science and among other he was
the Project Leader for the merger of Pfizer and Pharmacia in the Nordic
region.

”Orexo is an exciting company that I have followed for several years.
The company has a very interesting product portfolio that provides a
solid foundation for a commercial organization. I look forward to
developing and executing Orexo's strategy for sales and marketing of the
company's own products,” said Nikolaj Sørensen.

”Orexo has had a strong focus on commercial development since 2010 and
we are particularly pleased that we have succeeded in recruiting Nikolaj
Sørensen to be in charge of commercial operations. He brings broad
international commercial experience and his background suits the
company's strategy to market and sell its own products,” said Anders
Lundström, President and CEO of Orexo AB. “I am very happy to welcome
Nikolaj to Orexo's executive management team.”

For further information, please contact:
Anders Lundström, President and CEO, Orexo AB
Tel: +46 706 67 22 66
E-mail: anders.lundstrom@orexo.com (anders.lundstrom@orexo.com)

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. The company has four commercialized products,
several projects developed in partnership as well as three proprietary
development programs. Orexo's registered products are Abstral® for the
treatment of break through cancer pain, sold by Kyowa Hakko
Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill
Edluar™, sold by Meda in the USA, as well as two products for the
diagnosis of Helicobacter pylori which are being marketed by the
subsidiary Kibion. More information can be found at
www.orexo.com (http://www.orexo.com/).

Note
Orexo AB (publ) discloses the information provided in this press release
pursuant to the Securities Markets Act. The information was provided for
public release on September 16, 2011 at 10:30a.m. CET. This press
release has been prepared in both Swedish and English. In the event of
any discrepancy in the content of the two versions, the Swedish version
shall take precedence.